Table 4.
Comparison between transplanted and non-transplanted patients.
| No HSCT | HSCT | p-value | |
|---|---|---|---|
| No. of patients, n (%) | 13 (33.3) | 26 (66.6) | |
| Sex, n (%) | 0.036 | ||
| Male | 8 (61.5) | 7 (26.9) | |
| Female | 5 (38.5) | 19 (73.1) | |
| Age (months), median (p25–p75) | 2.3 (0.35–7.5) | 6 (3.9–9.1) | 0.065 |
| Age <6 months, n (%) | 8 (61.5) | 12 (46.2) | 0.365 |
| Diagnosis, n (%) | 0.858 | ||
| ALL | 9 (69.2) | 18 (69.2) | |
| B or T | 8–1 | 18–0 | |
| AML | 4 (30.8) | 7 (26.9) | |
| MPAL | 0 | 1 (3.8) | |
| CD10 (CALLA), n (%) | 0.356 | ||
| Negative | 11 (84.6) | 17 (65.4) | |
| KMT2A-r, n (%) | 5 (38.4) | 17 (65.4) | 0.091 |
| WBC count at diagnosis: | 1 | ||
| >300,000/mm3, n (%) | 4 (30.8) | 8 (30.8) | |
| Induction failure, n (%) | |||
| Yes | 4 (30.8) | 2 (7.7) | |
| Status, n (%) | |||
| Alive | 3 (23) | 17 (65.3) | |
| Dead before HSCTa, n (%) | 7 (53.8) | ||
| 5-year OS, % (ES) | 18.5 (26.3) | 60.4 (28.8) | 0.001 |
| 5-year OS withouta, % (ES) | 41.7 (50.4) | 60.4 (28.8) | 0.191 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HSCT, hematopoietic stem cell transplantation; OS, overall survival; SE, standard error; WBC, white blood cell.
a
Death due to treatment complications or refractory disease.